Cargando…

Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review

Nivolumab (PD-1 inhibitor) and other immune checkpoint inhibitors are used primarily to promote reactivation of anti-tumor immunity. However, due to their generalized immunorestorative properties, these agents may also trigger an unusual spectrum of side-effects termed immune-related adverse events....

Descripción completa

Detalles Bibliográficos
Autores principales:	van Eeden, Ronwyn, Rapoport, Bernardo L., Smit, Teresa, Anderson, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668214/ https://www.ncbi.nlm.nih.gov/pubmed/31396484 http://dx.doi.org/10.3389/fonc.2019.00659

Ejemplares similares

Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer
por: Rapoport, Bernardo L, et al.
Publicado: (2020)

Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study
por: Rapoport, Bernardo Leon, et al.
Publicado: (2018)

Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy
por: Jiang, Meilin, et al.
Publicado: (2020)

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Yang, Szu-Chun, et al.
Publicado: (2021)

Nivolumab-Induced Organizing Pneumonia in Management of Non-small Cell Lung Carcinoma: A Case Report
por: Habib, Tehmina, et al.
Publicado: (2023)

Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice
por: Anderson, Ronald, et al.
Publicado: (2018)

A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer
por: Liu, Chang, et al.
Publicado: (2021)

Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study
por: Egami, Saeka, et al.
Publicado: (2021)

Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer
por: Aiello, Marco Maria, et al.
Publicado: (2020)

Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers
por: Daher, Sameh, et al.
Publicado: (2021)

Frontiers in Pharmacology: Review Manuscript Targeting of the Neutrophil as an Adjunctive Strategy in Non-Small Cell Lung Cancer
por: Anderson, Ronald, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
por: Hu, Huabin, et al.
Publicado: (2020)

Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report
por: Arias Ron, David, et al.
Publicado: (2019)

Pulmonary side effects of nivolumab in a patient treated for gynecological malignancy
por: Ip, Joana, et al.
Publicado: (2018)

An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer
por: Jiang, Panpan, et al.
Publicado: (2021)

Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study
por: Awad, Mark M., et al.
Publicado: (2021)

Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study
por: Ogiwara, Toshiki, et al.
Publicado: (2021)

Treatment and relapse of interstitial lung disease in nivolumab‐treated patients with non–small cell lung cancer
por: Sata, Masafumi, et al.
Publicado: (2021)

Nivolumab in Metastatic Non–Small Cell Lung Cancer
por: Deel, Andrea
Publicado: (2016)

Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3
por: Rapoport, Bernardo L., et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Induced Pericarditis and Encephalitis in a Patient Treated With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report and Review of the Literature
por: Braden, Jorja, et al.
Publicado: (2021)

Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer
por: Goldman, Jonathan W., et al.
Publicado: (2019)

Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study
por: Awad, Mark M., et al.
Publicado: (2022)

Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review
por: Sam Saji, Alen, et al.
Publicado: (2023)

Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab
por: Seyed Jafari, S. Morteza, et al.
Publicado: (2020)

Case Report: Differential Genomics and Evolution of a Meningeal Melanoma Treated With Ipilimumab and Nivolumab
por: Burgos, Remberto, et al.
Publicado: (2022)

Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
por: Lind, Joline S. W., et al.
Publicado: (2010)

Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab
por: Cusato, Jessica, et al.
Publicado: (2019)

A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer
por: Suyanto, Suyanto, et al.
Publicado: (2019)

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
por: Botticelli, Andrea, et al.
Publicado: (2019)

Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
por: Dudzińska, Marta, et al.
Publicado: (2020)

Nivolumab and Hypofractionated Radiotherapy in Patients With Advanced Lung Cancer: ABSCOPAL-1 Clinical Trial
por: Ye, Hua, et al.
Publicado: (2021)

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
por: Passiglia, Francesco, et al.
Publicado: (2018)

Hyperprogressive disease in patients with non‐small cell lung cancer treated with nivolumab: A case series
por: Kanazu, Masaki, et al.
Publicado: (2018)

Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer
por: Ramagopalan, Sreeram, et al.
Publicado: (2021)

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review
por: Garon, Edward B., et al.
Publicado: (2023)

Editorial: Management of Immune-Related Adverse Events for Patients Undergoing Treatment With Checkpoint Inhibitors
por: Rapoport, Bernardo Leon
Publicado: (2019)

Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
por: Chai, Rong, et al.
Publicado: (2021)

Individualized Treatment for Advanced Non-Small Cell Lung Cancer: A Case Report and Literature Review
por: Sun, Qianqian, et al.
Publicado: (2022)

Pericardial Effusion With Tamponade in Lung Cancer Patients During Treatment With Nivolumab: A Report of Two Cases
por: Yamasaki, Masahiro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_40o6uh8qubfu9pe9man6qt273r